New data on lecanemab presented at the CTAD Alzheimer conference November 15, 2021 08:00 Non Regulatory Read more
DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer’s disease November 8, 2021 18:00 Non Regulatory Read more
New data published on ABBV-0805 in Neurobiology of Disease November 8, 2021 08:00 Non Regulatory Read more
New data on lecanemab to be presented at the 14[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference November 4, 2021 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET October 11, 2021 11:00 Non Regulatory Read more
Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway September 28, 2021 01:37 Regulatory Read more
New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease September 10, 2021 16:40 Non Regulatory Read more
Eisai presented latest data from the lecanemab clinical program at AAIC 2021 July 30, 2021 08:00 Non Regulatory Read more
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) July 21, 2021 08:00 Non Regulatory Read more
FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer’s disease June 23, 2021 22:11 Regulatory Read more
BioArctic receives patent in Japan for new antibodies targeting Alzheimer’s disease May 11, 2021 08:00 Non Regulatory Read more
Lecanemab (BAN2401) Phase 2b study in early Alzheimer’s disease published in peer-reviewed journal, Alzheimer’s Research & Therapy April 20, 2021 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – March 2021 on April 21 at 9.30 a.m. CET April 15, 2021 08:00 Non Regulatory Read more
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021 March 15, 2021 08:00 Non Regulatory Read more
Latest lecanemab data to be presented at the AD/PD™ congress March 5, 2021 08:00 Non Regulatory Read more
The Nomination Committee’s proposal for the election of board members in BioArctic AB February 12, 2021 08:00 Regulatory Read more
Eisai increases the number of participants in Clarity AD study February 3, 2021 08:05 Non Regulatory Read more
BioArctic receives European patent for new antibodies targeting Alzheimer’s disease January 27, 2021 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2020 on February 4 at 9.30 a.m. CET January 26, 2021 08:00 Non Regulatory Read more